Cardiological Findings in Patients with End-Stage Renal Failure Under Treatment with Erythropoietin

  • G. Schütterle
  • W. Kramer
  • R. Schäfer
  • J. Kaufmann
  • V. Wizemann
Conference paper


The extent of left ventricular myocardial hypertrophy is generally considered to be a predictor of cardiac morbidity and mortality (Devereux et al. 1984; Levy et al. 1988, 1990). The evolution of left ventricular hypertrophy has been causally related to coronary artery disease (CAD), arterial hypertension, and increased cardiac output (Devereux 1990; Messerli and Schmieder 1990; Koren et al. 1991). This is apparently also the case with patients with end-stage renal disease undergoing chronic intermittent hemodialysis treatment (Bullock et al. 1984; Kramer et al. 1986a,b; Harnett et al. 1988; Silberberg et al. 1989).Whether secondary hyperparathyroidism significantly contributes to myocardial fibrosis in patients on hemo- or peritoneal dialysis does, however, appear doubtful at the present time (London et al. 1987a,b; Mall et al. 1990; Hüting et al. 1991a,b).


Left Ventricular Hypertrophy Secondary Hyperparathyroidism Recombinant Human Erythropoietin Renal Anemia Left Ventricular Ejection Time 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bullock RE, Amer HA, Simpson I,Ward MK, Hall RJC (1984) Cardiac abnormalities and exercise tolerance in patients receiving renal replacement therapy, Br Med J 289: 1479–1484Google Scholar
  2. Devereux RB (1990) Does increased blood pressure cause left ventricular hypertrophy or vice versa Ann Intern Med 112: 157–158PubMedGoogle Scholar
  3. Devereux RB, Drayer JIM, Chien S, Pickering TG, Letcher RL, DeYoung JL, Sealey JE, Laragh JH (1984) Whole blood viscosity as a determinant of cardiac hypertrophy in systemic hypertension. Am J Cardiol 54: 592–595PubMedCrossRefGoogle Scholar
  4. Harnett JD, Parfrey PS, Griffiths SM, Gault MH, Barre P, Guttmann RD (1988) Left ventricular hypertrophy in end-stage renal disease. Nephron 48: 107–115PubMedCrossRefGoogle Scholar
  5. Hüting J, Kramer W,Wizemann V, Schütterle G (1991a) Effects of secondary hyperparathyroidism on left ventricular hypertrophy and function in patients on different renalreplacement therapies. In: Timio M, Wizemann V (eds) Cardionephrology. Wichtig, Milan, pp 119–122Google Scholar
  6. Hüting J, Kramer W, Kühn K, Schütterle G, Wizemann V (1991b) Risk factors for diastolic left ventricular dysfunction in patients on continuous ambulatory peritoneal dialysis (CAPD) In: Timio M, Wizemann V (eds) Cardionephrology. Wichtig, Milan, pp 321–324Google Scholar
  7. Klaus D, Schwarze D, Lederle RM, Saul F (1991) Behandlung mit rekombinantem humanem Erythropoietin. Nieren Hochdruckkrankheiten 20: 28–35Google Scholar
  8. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH (1991) Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 114: 345–352PubMedGoogle Scholar
  9. Kramer W,Wizemann V,Thormann J, Kindler M, Mueller K, Schlepper M (1986a) Cardiac dysfunction in patients on maintenance hemodialysis. I. The importance of associated heart disease in determining alteration of cardiac performance. Contrib Nephrol 52: 97–109Google Scholar
  10. Kramer W,Wizemann V, Lämmlein G,Thormann J, Kindler M, Schlepper M, Schütterle G (1986b) Cardiac dysfunction in patients on maintenance hemodialysis. II. Systolic and diastolic properties of the left ventricle assessed by invasive methods. Contrib Nephr 52: 110–124Google Scholar
  11. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP (1988) Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. Ann Intern Med 108: 7–13PubMedGoogle Scholar
  12. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP (1990) Prognostic implications of echocardiographically determined left ventricular mass in the framingham heart study. N Engl J Med 322: 1561–1566PubMedCrossRefGoogle Scholar
  13. London GM, DeVernejoul MC, Fabiani F, Marchais SJ, Guerin AP, Metivier F, London AMGoogle Scholar
  14. Llach F (1987a) Secondary hyperparathyroidism and cardiac hypertrophy in hemodialysis patients. Kidney Int 32: 900–907PubMedCrossRefGoogle Scholar
  15. London GM, Fabiani F, Marchais SJ, DeVernejoul MC, Guerin AP, Safar ME, Metivier F, Llach F (1987b) Uremic cardiomyopathy: an inadequate left ventricular hypertrophy. Kidney Int 31: 973–980PubMedCrossRefGoogle Scholar
  16. Low I, Grützmacher P, Bergmann M, Schoeppe W (1989) Echocardiographic findings in patients on maintenance hemodialysis substituted with recombinant human erythropoietin. Clin Nephrol 31: 26–30PubMedGoogle Scholar
  17. Messerli FH, Schmieder RF (1990) Arterielle Hypertonie, linksventrikuläre Hypertrophie und plötzlicher Herztod. Dtsch Med Wochenschr 115: 1682–1687PubMedCrossRefGoogle Scholar
  18. Mall G, Huther W, Schneider J, Lundin P, Ritz E (1990) Diffuse intermyocardocytic fibrosis in uraemic patients. Nephrol Dial Transplant 5: 39–44PubMedGoogle Scholar
  19. Sahn DJ, DeMaria A, Kisslo J,Weyman A (1978) Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58: 1072–1083Google Scholar
  20. Silberberg JS, Barre PE, Prichard SS, Sniderman AD (1989a) Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36: 286–290PubMedCrossRefGoogle Scholar
  21. Silberberg JS, Rahal DP, Patton DR, Sniderman AD (1989b) Role of anemia in the pathogenesis of left ventricular hypertrophy in end-stage renal disease. Am J Cardiol 64: 222–224PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • G. Schütterle
  • W. Kramer
  • R. Schäfer
  • J. Kaufmann
  • V. Wizemann

There are no affiliations available

Personalised recommendations